Second-quarter R&D expense increased 13% to $248.3 million from $218.8 million, with adjusted R&D rising to $242.0 million from $211.2 million. Reported SG&A increased 22% to $1,134.5 million from $928.7 million, primarily reflecting a $177.8 million charge related to the planned Tyrvaya sale. Adjusted SG&A declined to $820.5 million from $826.0 million, reducing adjusted SG&A as a percentage of revenue to 22% from 23%.
Key facts
U.S. GAAP selling, general and administrative expense for Q2 2026: $1,134.5 million and adjusted SG&A: $820.5 million representing 22% of total revenues source
Research and development expense for Q2 2026: $248.3 million and adjusted R&D: $242.0 million representing 6% of total revenues source